Clinical Trial Update: A Study of Efimosfermin Alfa in Adults With Hepatic Impairment [Phase 1]

View source ↗

Summary

Phase 1 study evaluating efimosfermin alfa in adults with hepatic impairment, targeting non-alcoholic fatty liver disease; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease

Drugs mentioned

• Efimosfermin Alfa (efimosfermin alfa)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Non-alcoholic Fatty Liver Disease | Phase 1 | Status: RECRUITING